October 24th 2024
Nina Vadiei, PharmD, BCPP, a clinical associate professor at UT Austin and a clinical pharmacy specialist in psychiatry at San Antonio State Hospital, discusses her career as a psychiatric pharmacist.
The pharmacist and MTM services
October 15th 2011^MTM services are additional to provision of a drug product and include a broad range of pharmacists' activities within the scope of pharmacy practice. ^An example of MTM includes creating a medication treatment plan. ^Another example is monitoring and evaluating a patient's response to therapy.
FDA enters consent decree of permanent injunction against Florida drug companies
October 11th 2011FDA recently announced that the District Court for the Middle District of Florida entered a consent decree that prohibits Hill Dermaceuticals Inc., Hill Labs Inc., and certain individuals from introducing adulterated drugs into interstate commerce.
FDA approves Combivent Respimat Inhalation Spray for patients with COPD
October 10th 2011FDA has approved ipratropium bromide and albuterol (Combivent Respimat Inhalation Spray, Boehringer Ingelheim) for patients using a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
FDA approves sitagliptin and simvastatin combination therapy
October 7th 2011FDA has approved sitagliptin and simvastatin (Juvisync, MSD International GmbH Clonmel), a fixed-dose combination prescription medication that contains 2 previously approved medications in 1 tablet for use by adults who need both sitagliptin and simvastatin.
NSAIDs increase miscarriage risk in early pregnancy
September 13th 2011Nonsteroidal anti-inflammatory drugs (NSAIDs) should be used with caution during pregnancy, as exposure may increase the risk of spontaneous abortion, reported a study published online September 6 in the Canadian Medical Association Journal.
FDA panel recommends approval of rivaroxaban for stroke prevention
September 9th 2011An FDA advisory panel voted 9-2 (with 1 abstention) to recommend approval for rivaroxaban (Xarelto, Johnson & Johnson and Bayer AG), an oral, once-daily anticoagulant as a treatment to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation.